By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Aria Diagnostics said today that it has raised $52.7 million in Series C funding that it will use to commercialize a prenatal test to detect fetal aneuploidies such as trisomy 21.

New investors include Meritech Capital Partners and an undisclosed mutual fund group. Existing investors Venrock and Domain Associates also participated in the round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.